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Microbes are exposed to compounds produced
bymembers of their ecological niche, includingmole-
cules with antibiotic or antineoplastic activities. As
a result, even bacteria that do not produce such
compounds can harbor the genetic machinery to
inactivate or degrade these molecules. Here, we
investigated environmental actinomycetes for their
ability to inactivate doxorubicin, an aminoglycosy-
lated anthracycline anticancer drug. One strain,
Streptomyces WAC04685, inactivates doxorubicin
via a deglycosylation mechanism. Activity-based
purification of the enzymes responsible for drug inac-
tivation identified the NADH dehydrogenase compo-
nent of respiratory electron transport complex I,
which was confirmed by gene inactivation studies.
A mechanism where reduction of the quinone ring of
the anthracycline by NADH dehydrogenase leads to
deglycosylation is proposed. This work adds anti-
cancer drug inactivation to the enzymatic inactivation
portfolio of actinomycetes and offers possibilities for
novel applications in drug detoxification.
INTRODUCTION
Soil microbes, and particularly the actinobacteria, are prolific
producers of natural products. Many of these compounds
demonstrate antibacterial or anticancer activity and so have
been applied to human medicine through clinical use as antibi-
otics or antineoplastic drugs. In the environment, many soil
organisms harbor enzymes that modify or degrade these prod-
ucts to avoid their toxic effects. Therefore, environmental
bacteria may represent a previously uninvestigated source of
unique strategies to detoxify antineoplastics.
On this basis, we sought to probe a library of environmental
isolates for the ability to catalyze the detoxification of antineo-
plastic drugs. Understanding how environmental bacteria might
detoxify anticancer therapeutics could have many benefits. The
degradation of these toxic products could be applicable to
safely discarding waste from the pharmaceutical industry,
including remediating spills; might be life-saving if used to re-
move excess drug administered as an accidental overdose; or,Chemistry & Biology 19, 1255–1most tantalizing, careful targeting of drug inactivation to nontu-
mor tissues could potentially remove the side effects for patients
undergoing chemotherapy without compromising the efficacy
of the treatment. The downstream potential of a novel environ-
mental detoxification mechanism would depend on its precise
nature; the first step must be the identification of new catalysts
capable of drug detoxification.
For this proof-of-principle study, the anthracycline antineo-
plastic doxorubicin was selected because it is a natural product
of an actinobacteria, Streptomyces peucetius var. casieus.
Doxorubicin also has antibiotic activity, providing a simple resis-
tance assay for screening of environmental bacteria. Doxoru-
bicin is the most commonly used anthracycline drug and is
chosen for treatment of a range of cancers, including carci-
nomas, soft tissue sarcomas, and hematological malignancies.
Anthracyclines are thought to inhibit the growth of cancer cells
through multiple mechanisms, including intercalation in DNA,
which leads to inhibition of both DNA replication and RNA
transcription; generation of free radicals, resulting in DNA
damage and lipid peroxidation; DNA binding and alkylation;
DNA cross-linking; interference with DNA unwinding, DNA
strand separation, and helicase activity; direct membrane
damage due to lipid oxidation; and inhibition of topoisomerase
II (reviewed in Gewirtz, 1999). The use of any anthracycline
drug, however, is limited, due to cumulative toxicity. For doxoru-
bicin, the maximum cumulative dose is approximately 550–
700 mg/m2 for otherwise healthy adults (Novopharm, 1996).
Although several potential side effects are known, including
mucosal toxicity, alopecia, and secondary malignancy, cardio-
toxicity is the most troubling. This toxicity is thought to be due
to free radical damage and disruption of iron homeostasis
initiated by the drug and enhanced by the cardiac tissues’ dimin-
ished production of reactive oxygen species (ROS)-degrading
enzymes, such as superoxide dismutase, glutathione peroxi-
dase, and catalase (Licata, et al., 2000; Minotti, et al., 2000;
Singal, et al., 2000).
In bacteria, anthracyclines like doxorubicin inhibit growth
through similar mechanisms to those that cause cytotoxicity in
humans, particularly the induction of DNA/RNA damage. Some
resistance has been documented in E. coli K-12, but strains
deficient in antibiotic efflux due to mutation or deletion of the
acr locus were found to be drug sensitive (Kaur, 1997). For our
purposes, we did not want to investigate efflux strategies, but
rather wished to focus on identifying new catalysts capable
of drug detoxification. Therefore, we screened a collection of264, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1255
Figure 1. Structures of Doxorubicin and
Aglycone Products Detected in This Study
Structure of 7-deoxydoxorubicinol is supported
by MS/MS data (Figure S1), and the structure of
7-deoxydoxorubicinolone is supported by 13C
NMR data (Figure S2). See also Figures S1 and S2.
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and then screened a subset for degradation activity. After
purification and identification of the doxorubicin degradation
proteins, we report that the inactivation of anticancer anthracy-
clines can occur through reductive deglycosylation mediated
by the NADH dehydrogenase component of the respiratory elec-
tron transport complex I. This understanding of anticancer drug
inactivation in bacteria gives proof-of-principle for the screening
of environmental isolates to identify novel degradation strategies
for antineoplastics.
RESULTS
Screen of Environmental Actinomycetes
for Anthracycline Degradation
Drug tolerance to doxorubicin among bacterial strains was
estimated by calculating the minimum inhibitory concentrations
(MIC) for several sample strains from our set of actinomycetes
collected from various locales (D’Costa, et al., 2006). For plank-
tonic cells growing in liquid broth, MICs ranged from less than
2 mg/ml to over 200 mg/ml; the median of 12 strains was
3.2 mg/ml. Strains were more resistant to doxorubicin when
grown on solid media, so a concentration of 150 mg/ml was
used in solid agar to screen a library of 626 soil actinomycetes
for resistance to doxorubicin. The screen showed that 67% of
strains were resistant to 150 mg/ml doxorubicin; selected strains
were subsequently assessed for their MIC using liquid media.
One of these strains, WAC04685, had a broth MIC > 200 mg/ml
and was determined to be related to Streptomyces zaomycecius
and Streptomyces phaeochromogenes by 16S rDNA analysis
(99% sequence identity). This strain was selected for further
study because of its robust growth and ability to degrade anthra-
cyclines (detailed below).
The methanolic extracts of cultures of Streptomyces
WAC04685 grown in the presence or absence of doxorubicin
were analyzed by reverse phase high performance liquid
chromatography (HPLC) with mass spectrometry detection
(LC/MS). A new peak that retained the anthracycline UV/visible
spectroscopic properties, namely an absorbance maximum at1256 Chemistry & Biology 19, 1255–1264, October 26, 2012 ª2012 Elsevier Ltd All rights res480 nm, was observed in the extract
from cultures grown with the drug (data
not shown). The 401.7 m/z ion, detected
in positive ion mode, is consistent
with the mass of 7-deoxydoxorubicinol
(400.1 g/ml), which is a deglycosylated
alcohol derivative of doxorubicin (Fig-
ure 1). The predicted structure was con-
firmed by tandem MS/MS analysis on
both doxorubicin and the reaction pro-
duct purified from HPLC, showing thatboth molecules share the same decomposition fragments
(305, 321, and 346 m/z) that are consistent with anthracyclines
(Figure S1 available online). This metabolism of doxorubicin
was observed regardless of when the drug was introduced,
implying that the degradation machinery is constitutively
expressed.
Purification and Characterization of an Anthracycline
Degradation Enzyme and Its Products
Purification of the putative anthracycline degradation enzyme
from natural abundance in Streptomyces WAC04685 was
undertaken using ammonium sulfate precipitation in addition
to a series of hydrophobic, dye affinity, gel filtration, cation
exchange, and hydroxyapatite chromatographic steps. To
quickly detect the presence of doxorubicin degradation activity
in the resulting fractions after each separation technique, crude
samples were reacted with doxorubicin then analyzed by thin
layer chromatography (TLC). Empirical testing showed that
degradation of doxorubicin was improved by adding nicotin-
amide adenine dinucleotide phosphate (NADPH) to the crude
extracts along with doxorubicin. Under the conditions used,
two different product spots were well separated and the intrinsic
red color from the anthracycline corewas sufficient for detection.
The sensitivity of the TLC was comparable to that of LC/MS for
the detection of doxorubicin degradation products (data not
shown). Analysis of active fractions by LC/MS in positive ion
mode also demonstrated two product peaks at 399 and 402m/z,
which had a difference of two mass units. The masses of the
two products are consistent with 7-deoxydoxorubicinolone
(398.1 g/mol) and 7-deoxydoxorubicinol (400.1 g/mol) (Figure 1).
Despite further efforts at purification, while using NADPH as a
cofactor, it was not possible to separate activity producing
only 7-deoxydoxorubicinolone or 7-deoxydoxorubicinol; all
reactions produced some of both products.
Purified active protein fractions were visualized by SDS-PAGE
and resulted in the identification of three protein bands with
the apparent sizes of 24, 38, and 50 kDa (Figure 2A). Native
PAGE of the same purified fractions also indicated the presence
of three bands with different apparent abundance (Figure 2B).erved
Figure 2. Polyacryamide Gel Electrophoresis of Purified Doxoru-
bicin Degradation Enzymes
(A) Denaturing SDS-PAGE.
(B) Native PAGE. These bands were excised and identified as members of the
NADH dehydrogenase complex (NuoE, NuoF, and NuoG) by mass spec-
trometry of proteolytic fragments. See also Table S1.
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taining activity, suggestive of an enzyme complex.
Tryptic digestion followed by peptide sequencing by mass
spectrometry fromboth the native and SDS-PAGE gels identified
similar peptides (Table S1). The best score for one of the proteins
on both gel types was for NuoF; this protein was identified as the
top hit for all three of the protein bands present on the native
PAGE gel. NuoF is a peripheral protein that is part of the NADH:
ubiquinone oxidoreductase complex and is thought to be
involved in NADH binding (Friedrich and Scheide, 2000). Other
related proteins, including NuoG and NuoE, were also detected,
although with lower scores, from the native PAGE and SDS-
PAGE bands.
Purified NADH dehydrogenase, consisting of NuoEFG from
Streptomyces WAC04685, was reacted with NADPH and
doxorubicin; using one-dimensional (1D) and two-dimensional
(2D) nuclear magnetic resonance (NMR) spectroscopy, the
enzyme-modified product was found to be consistent with
7-deoxydoxorubicinolone (Figure S2). The other product that
had been detected in crude protein preparations, 7-deoxydox-
orubicinol, was not detected in NMR experiments. Purified
NADH dehydrogenase was also used for kinetic analyses in
reactions that initially contained NADPH, but during optimiza-
tion of the kinetic experiments, NADH was found to be a
much better cofactor. When NuoEFG complex was reacted
with excess NADH, it was found to have a Km of 95 ± 16 mM
and Vmax of 2.06 mmol/s for doxorubicin, demonstrating a kcat
of 720/s.
The product purified from Streptomyces WAC04685 NADH
dehydrogenase reactions, 7-deoxydoxorubicinolone, lacks anti-
microbial activity as assessed by liquid MIC tests against several
Streptomyces strains, even those that are doxorubicin-sensitive
(Table 1).Chemistry & Biology 19, 1255–1Genome Sequencing of StreptomycesWAC04685
Initially, peptide-mass identification of NuoE, NuoF, and NuoG
from Streptomyces WAC04685 was based on comparison to
proteins from Streptomyces coelicolor. It was unclear, based
on this data, if all three proteins were involved or required for
the degradation of doxorubicin in Streptomyces WAC04685.
Thus, having established thatWAC04685 catalyzes the degrada-
tion of doxorubicin into 7-deoxydoxorubicinolone, a thorough
analysis of the strain itself was desired. Seeking information
about taxonomy, possible production of anthracyclines, as well
as the doxorubicin resistance mechanisms, a draft genome
sequence of WAC04685 was determined on the Illumina plat-
form. After assembly, the genome was revealed to be about
7.8 Mbp and was in 1,916 contigs, encoding 7,716 open reading
frames. No plasmids were detected. The N50 was 8,566, and the
percentage guanine + cytosine base pairs in nucleotide
sequence (GC%) was 71.37%.
From the genome sequence, 16S rDNA analysis indicated
that WAC04685 is closely related (99% sequence identity) to
both Streptomyces zaomycecius and Streptomyces phaeochro-
mogenes. Little has been reported about these two strains, but
neither has been documented to produce or be resistant to
anthracyclines.
WAC04685 copiously produces an orange-red pigment when
cultured, which is reminiscent of the color of anthracyclines.
However,WAC04685 is unlikely to be an anthracycline producer,
because a search for homologs of Streptomyces peucetius
DpsF (polyketide cyclase) and DnrD (catalyzes closure of the
final anthracycline ring) (Grimm, et al., 1994; Madduri and
Hutchinson, 1995a, 1995b) identified no genes above the cutoff
of e10.
The toxicity of anthracyclines is in part due to the genera-
tion of reactive oxygen species (ROS), so the WAC04685
genome was searched for homologs of superoxide dismutase,
catalase, and glutathione peroxidase. Two distinct genes
were found with similarity to superoxide dismutases, one with
similarity to glutathione peroxidase, and at least two genes
with similarity to catalase. Comparatively, analysis suggests
that S. coelicolor M145 encodes three distinct genes with
similarity to superoxide dismutases, one with similarity to
glutathione peroxidase, and four genes with similarity to
catalase. Surveying other sequenced Streptomyces indicates
that, in all genomes so far, there is at least one representa-
tive of each of the ROS-detoxifying genes queried. This
analysis gives no estimate of total expression levels for these
putative protein products, but at least documents that
Streptomyces are generally well-equipped to deal with reactive
oxygen stress.
Finally, the assembled Streptomyces WAC04685 draft
genome was searched for homologs of the nuo genes; three
contigs were identified that contained segments of the ex-
pected 14 gene locus. Based on similarity, these contigs
contained nuoA-nuoF, fragments of nuoG, and nuoJ-N.
Intracontig gaps were bridged by PCR and sequenced to
assemble the nuoABCDEFGHIJKLMN locus that constitutes
the electron transport complex I. No additional homologs of
nuo genes were identified with >40% similarity, leading to the
prediction that there is a single copy of each of the nuo genes
located in a single continuous locus. Comparison of 14264, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1257
Table 1. MIC for Selected Streptomyces Strains Tested against Anthracycline Drugs Doxorubicin, Daunorubicin, and the Doxorubicin
Aglycone Product, 7-Deoxydoxorubicinolone
Strain
Compound
Doxorubicin 7-Deoxydoxorubicinolone Daunorubicin
Streptomyces sp. Mg1a 1.56 >200 ND
S. sp. Waspa 25 >200 0.78–1.56
S. sp. SPB74a 0.78 >200 n.d.
S. sp. SPB78a 1.56 >200 n.d.
S. sviceus ATCC 29083a 0.78 >200 n.d.
Saccharopolyspora erythraea 2338a 6.25 >200 1.56
WAC04685b >200 >200 12.5
WAC04741b 12.5 >200 n.d.
Streptomyces coelicolor M145 3.125 ND 0.78
Streptomyces peucetius var. casius ATCC 29050 3.125 ND 0.78
ND, not determined.
aBroad strain collection.
bWright actinomycete collection.
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either one or two BLAST-detectable copies of each of the
nuo genes. Most (>75%) strains have only one copy of nuoE
and nuoG, while about half of the strains investigated have
two copies of nuoF. This, together with the high predicted
sequence coverage and small average gap size of the genome
assembly, supports our hypothesis that there is a single Nuo
locus.
Investigations of the StreptomycesWAC04685
nuo Locus
Among the NuoE, NuoF, and NuoG proteins that make up the
NADH dehydrogenase, only NuoF is predicted to have NADH
binding function (Friedrich and Scheide, 2000). Our prior
analysis had showed that there was a single copy of nuoF in
WAC04685, so it was targeted for insertional inactivation
in order to determine if doxorubicin could still be inactivated
in the absence of intact NuoF. Disruption of nuoF resulted in
a strain that was no longer capable of doxorubicin inactivation
(Figure 3), confirming the role of NADH dehydrogenase in
doxorubicin degradation. In these reactions, NADH was used
as the cofactor with crude lysate and confirmed the production
of a sole product, 7-deoxydoxorubicinolone, by the wild-type
WAC04685 under these conditions (Figure 3). The nuoF-
inactivated strain nevertheless retained its drug resistance
phenotype (MIC > 200 mg/ml doxorubicin), suggesting
additional modes of drug resistance present in Streptomyces
WAC04685.
Doxorubicin Degradation Ability among Other Bacteria
Based on the findings that NADH dehydrogenase is responsible
for doxorubicin degradation in Streptomyces WAC04685 and
knowledge that the nuoEFG genes are widespread, additional
Streptomyces strains were tested for doxorubicin degrada-
tion ability. WAC04741, Streptomyces coelicolor M145, and
Streptomyces peucetius var. casius ATCC 29050 all demon-
strated the ability to degrade doxorubicin in TLC and LC/MS
analysis (data not shown).1258 Chemistry & Biology 19, 1255–1264, October 26, 2012 ª2012 EDISCUSSION
Doxorubicin Resistance in Environmental Bacteria
The initial screen of our environmental actinomycete library
showed that the majority of strains (67%) tested were resistant
to doxorubicin at 150 mg/ml; this is the first report, to our knowl-
edge, of anticancer drug resistance among environmental
bacteria. The prevalence of resistance was surprising and the
mechanisms of this resistance have not been elucidated. For
our purposes, we hoped to discover mechanisms of drug
degradation among the isolates, so we elected to focus on
the novel doxorubicin inactivation identified in Streptomyces
WAC04685. Here, the enzymatic conversion of doxorubicin
to 7-deoxydoxorubicinolone has been documented and 7-
deoxydoxorubicionolone has been shown to be many times
less toxic than doxorubicin itself; thus, a bacterial doxorubicin
degradation and detoxification system was successfully identi-
fied. Additional strains and other species of bacteria were shown
to catalyze the same process, indicating that the degradation
activity is not unique to StreptomycesWAC04685. This provides
proof-of-principle for the concept of bacterial resistance to
anticancer drugs, and future studies could target additional
antineoplastic drugs outside of the anthracycline group.
Isolation of the NADH Dehydrogenase Complex
Consisting of NuoE, NuoF, and NuoG
Activity-based purification of the doxorubicin degradation
protein led to the identification of NuoE, NuoF, and NuoG.
Together, NuoE, NuoF, and NuoG make up the NADH dehydro-
genase module of the 14-subunit respiratory electron transport
complex I. The NADH dehydrogenase module protrudes from
the rest of the membrane-anchored complex into the cytosol
and is unique to bacterial NADH:ubiquinone oxidoreductases
(reviewed by Friedrich and Scheide, 2000). During purification,
the NADH dehydrogenase module was removed from the other
complex I proteins.
The role of NuoF in NADH binding (Friedrich and Scheide,
2000) is likely why the complex showed affinity for Bluelsevier Ltd All rights reserved
Figure 3. HPLC Spectra of Doxorubicin
Degradation by Streptomyces WAC04685
Wild-type and nuoF::pSET152 Strains
Intact doxorubicin (dashed line) was applied as
a control. Degradation reactions were performed
using crude extracts of Streptomyces WAC04685
wild-type with either NADH (solid line) or NADPH
as a cofactor (dashed and dotted line) or nuoF::
pSET152 with NADH (dotted line), demonstrating
the loss of degradation ability in the knockout. See
also Tables S2 and S3.
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bands on the two PAGE gel types (Figure 2). Blue Sepharose
was used in one step of the purification, and the Cibacron blue
dye is an analog of nicotinamide adenine dinucleotide (NAD)/
nicotinamide adenine dinucleotide phosphate (NADP) that
frequently is used to purify NAD/NADP-requiring enzymes.
Likely, NuoF was immobilized on the Blue Sepharose, and the
other NADH dehydrogenase components, NuoE and NuoG,
were purified by virtue of their interaction with NuoF. On the
SDS-PAGE gel, NuoE, NuoF, and NuoG migrate faster than
their expected sizes of 25.6, 48.8, and 78.8 kDa, respectively.
On the native PAGE gel, the three bands likely reflect different
proportions of NuoF interacting with NuoE and/or NuoG.
Activity of Streptomyces WAC04685 Extracts against
Doxorubicin with NADH and NADPH
During the experiments, both NADPH and NADH were used
as cofactors for the enzymatic inactivation of doxorubicin by
the NuoEFG complex. Initially, NADPH was used because its
empirical addition to crude extracts of WAC04685 improved
the production of two aglycone degradation products: 7-deoxy-
doxorubicinol and 7-deoxydoxorubicinolone. Use of NADPH
was continued until the identification of the degradation enzyme
as NADH dehydrogenase (NuoEFG complex). Since the well-
studied NADH dehydrogenase of the respiratory chain from
E. coli is strictly restricted to using NADH, not NADPH (Dancey,Chemistry & Biology 19, 1255–1264, October 26, 2012 ªet al., 1976), the activity of NADH
dehydrogenase from WAC04685 was
re-evaluated with NADH as a cofactor.
Not only did purified NADH dehydroge-
nase show improved conversion of
doxorubicin to 7-deoxydoxorubicinolone
when NADH was used, but crude lysates
reacted with NADH showed only the
production of 7-deoxydoxorubicinolone,
whereas crude lysates in the presence
of NADPH produced 7-deoxydoxorubici-
nolone and 7-deoxydoxorubicinol.
The two aglycone products, 7-deoxy-
doxorubicinol and 7-deoxydoxorubicino-
lone, differ only in the state of the side
chain carbonyl group at C-13 (Figure 1).
Analogous to 7-deoxydoxorubicinol,
C-13 alcohol forms of glycosylated an-
thracycline drugs are known. The drug
daunorubicin is an anthracycline closelyrelated to doxorubicin, differing in that the hydroxyl at C-14 is
absent in daunorubicin. The reduced C-13 alcohol forms of
the drugs are called daunorubicinol or doxorubicinol, respec-
tively. In humans, the liver cytosol contains carbonyl reductase,
aldose reductase, and dihydrodiol dehydrogenase 2, which
require NADPH and convert daunorubicin to daunorubicinol
(Ohara, et al., 1995). Daunorubicinol is less toxic than the
ketone form of the drug, and carbonyl reductase in particular
was strongly induced in the presence of daunorubicin, leading
to a drug-resistant phenotype (Ax, et al., 2000). BLAST analy-
sis of our Streptomyces WAC04685 genome sequence indi-
cates the presence of genes encoding potential homologs
of carbonyl reductase, aldose reductase, and dihydrodiol
dehydrogenase 2 (identity > 30%, e values > e11). In reactions
with crude lysate, these proteins could convert 7-deoxydoxor-
ubicinolone to 7-deoxydoxorubicinol in the presence of
NADPH.
Based on these findings, NADH dehydrogenase uses
NADH as the cofactor to produce 7-deoxydoxorubicinolone
from doxorubicin. When NADPH was used with purified
NADH dehydrogenase, 7-deoxydoxorubicinolone was the sole
product, which may suggest that some NADH was copurified
with the enzyme complex. When NADPH was used with crude
lysates, 7-deoxydoxorubicinol was produced in addition to
7-deoxydoxorubicinolone, likely because the NADPH was
stimulating the action of carbonyl reductase or similar proteins2012 Elsevier Ltd All rights reserved 1259
Figure 4. Scheme for the Mechanism of
Inactivation of Doxorubicin by NADH Dehy-
drogenase
Two doxorubicin semiquinones disproportionate
to form the doxorubicin hydroquinone, which
is unstable and decomposes to 7-deoxydoxor-
ubicinolone and the sugar daunosamine (Lea
et al., 1990; Gille and Nohl, 1997). 7-deoxydox-
orubicinolone can be converted to 7-deoxydox-
orubicinol by the action of cytoplasmic NADPH-
dependent carbonyl reductases; therefore,
7-deoxydoxorubicinol was only observed in
reactions with NADPH and crude cell extracts.
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tion with NADH as a cofactor, and so reactions with NADH
and crude lysate do not show the presence of 7-deoxydoxoru-
bicinol. This establishes that NADH dehydrogenase is involved
in the deglycosylation of doxorubicin, generating the aglycone
7-deoxydoxorubicinolone. The observation of 7-deoxydoxoru-
bicinol in some experiments was likely due to the use of
NADPH cofactor in assay of crude lysates containing carbonyl
reductase or similar proteins; 7-deoxydoxorubicinol is not
a direct product of NADH dehydrogenase.
Role of NADH Dehydrogenase in Doxorubicin
Degradation
Our findings indicate that NADH dehydrogenase is an enzyme
complex essential for the degradation of doxorubicin in Strepto-
myces WAC04685. This enzyme initiates the mechanism that
converts doxorubicin into nontoxic 7-deoxydoxorubicinolone.1260 Chemistry & Biology 19, 1255–1264, October 26, 2012 ª2012 Elsevier Ltd All rights resPurification of NADH dehydrogenase
components NuoE, NuoF, and NuoG
from Streptomyces WAC04685 demon-
strate that the enzymes are sufficient
to achieve the degradation of doxoru-
bicin in vitro. Inactivation of nuoF in
Streptomyces WAC04685 showed that,
in the absence of the normal nuo locus,
the ability to degrade doxorubicin is
impaired. Therefore, we conclude that
NADH dehydrogenase is responsible for
degrading doxorubicin.
A scheme for the enzymatic produc-
tion of doxorubicin aglycone catalyzed
by the exogenous NADH dehydrogenase
of mammalian cardiac tissue had previ-
ously been proposed based on one-
electron reduction of the anthracycline
quinone ring, leading to the loss of the
daunosamine sugar (Gille and Nohl,
1997). The intermediates of this reaction
had been the subject of prior pulse-
radiolysis studies documenting the
chemistry of the one- and two-electron
reduction mechanisms (Lea, et al.,
1990). The production of 7-deoxydoxor-
ubicinolone from bacterial NADH dehy-drogenase likely follows the same scheme (Figure 4). This
process of reductive deglycosylation is significant for two
main reasons: anthracycline aglycones are much more hydro-
phobic than the glycosylated counterparts, and therefore can
enter membranes, and anthracycline semiquinones can give
rise to O2,
 radicals by autoxidation (Doroshow and Davies,
1986; Gille and Nohl, 1997). Anthracycline aglycone semiqui-
nones can also be formed by NADH dehydrogenase-catalyzed
reduction of the quinone ring (Gille and Nohl, 1997). The anthra-
cycline aglycone semiquinones then divert an electron to
H2O2, forming HO, and OH
; these reactive oxygen species
(ROS) then cause toxicity to the host cell (Gille and Nohl,
1997). To our knowledge, this is the first report of NADH
dehydrogenase action on anthracyclines operating in bacteria
and suggests that bacteria could be used as model systems
for additional studies of dehydrogenase-based anthracycline
toxicity.erved
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7-Deoxydoxorubicinolone in Prokaryotes
and Eukaryotes
Our characterization of the effect of anthracycline aglycones on
intact cells in MIC experiments showed that these are less toxic
than intact anthracyclines in bacteria, in contrast to aglycone-
linked human cardiac toxicity. In humans, cardiac tissue is
uniquely susceptible to anthracycline semiquinone toxicity,
because of the production of an exogenous NADH dehydroge-
nase (Rasmussen and Rasmussen, 1985) and because of cata-
lase activity that is 2% to 4% of that in liver or kidney (Thayer,
1977). Essentially, the exogenous NADH dehydrogenase
converts doxorubicin to 7-deoxydoxorubicinolone, but then
7-deoxydoxorubicinolone can be used as a substrate for further
one-electron reduction by NADH dehydrogenase with concom-
itant production of ROS. This reductive process does not
degrade the aglycones, and so they can continue to redox cycle,
produce ROS, and cause damage.
The higher levels of catalase, superoxide dismutase, and
glutathione peroxidase in bacterial cells relative to human
cardiac tissue may account for the different response to the
same compound between bacterial and eukaryotic cardiac cells.
Bacterial cells are much more competent at dealing with the
outcomes of anthracycline semiquinone oxidation-reduction
cycling and the resulting reactive oxygen species (ROS) evolved.
The aglycone molecules may accumulate in membranes due to
their hydrophobicity; the rapid growth and division of bacterial
cells relative to eukaryotic cardiac tissue may also explain the
differential effect of anthracycline aglycones in prokaryotes
and eukaryotes.
Physiological Effects of Doxorubicin Degradation
in Bacteria or Potential Therapeutics
Streptomyces WAC04685 has been demonstrated to degrade
doxorubicin. However, this degradation may play a subordinate
role in resistance compared to other factors, such as efflux.
Streptomyces WAC04685 is highly resistant, with an MIC >
200 mg/ml; but inactivation of nuoF had no impact on resistance,
despite being unable to convert doxorubicin to 7-deoxydoxoru-
bicinol in vitro. This shows that the degradation of doxorubicin
is not essential for the survival of these bacteria, and so the
degradation does not strongly affect the resistance of the
organism. Nonetheless, based on these findings, novel strate-
gies to improve the quality-of-life of cancer patients could be
envisaged.
The essential issue with chemotherapy is that the drugs do not
selectively target tumor tissue, and therefore numerous side
effects occur that significantly impact quality-of-life for chemo-
therapy patients. Our findings reveal the mechanism for the
bacterial inactivation of doxorubicin. This could be exploited to
detoxify the drug in nontumor tissues. Recently, new vectors
to allow the overexpression of target proteins in lactobacilli
have been developed in order to allow in situ production of
biotherapeutics by intestinal lactobacilli (Duong et al., 2011).
Thus, future efforts could attempt to engineer probiotic bacteria
that overproduce NADH dehydrogenase in the gut of treated
humans, with the goal of reducing active drug concentration in
the gut. This in situ degradation of drug in nontarget tissues
could be protective against the gastrointestinal side effects ofChemistry & Biology 19, 1255–1chemotherapy with anthracyclines. In the future, we will continue
to survey environmental bacteria for additional strategies for the
degradation of these antitumor drugs. Decolorizing reactions,
which would involve breaking down the anthracycline core,
could be of additional interest. Environmental bacteria, like
Streptomyces WAC04685, have also been revealed here to be
of potential utility for fermenting anthracyclines into nontoxic
products, perhaps if bulk disposal was desired.
For the first time, a systematic screen of environmental
bacteria has been shown to identify strains able to resist and
metabolize antineoplastic compounds. This expands our under-
standing of the antibiotic resistome (D’Costa, et al., 2006, 2007)
to include other drugs, such as anticancer compounds, that
also have antibiotic activity. Further screening of environmental
bacteria for the resistance or ability to metabolize additional
antitumor drugs could give even more new strategies to improve
the quality-of-life of cancer patients undergoing chemotherapy.SIGNIFICANCE
Environmental bacteria are exposed to a wide variety of
potentially lethal compounds, as some organisms are
producers of antibiotic and/or antineoplastic compounds.
This study establishes that nonproducer soil isolates can
harbor the biological machinery required to degrade and
inactivate anticancer therapeutics. A library of environ-
mental isolates was screened for resistance to doxorubicin,
a widely used human chemotherapy drug. In particular, the
isolate WAC04685 was selected and has been shown
to degrade doxorubicin into 7-deoxydoxorubicinolone in
a reaction catalyzed by NADH dehydrogenase, a three-
protein complex. The identity of purified 7-deoxydoxorubici-
nolone was verified by NMR and shown to be nontoxic to
bacteria at concentrations over 200 mg/ml.
Production of deglycosylated anthracyclines, like 7-deox-
ydoxorubicinolone, have also been documented in treated
mammalian tissues. Prior mechanistic work suggested
that exogenous NADH dehydrogenase of cardiac tissue
also catalyzes the reductive deglycosylation of anthracy-
clines. To our knowledge, our study is the first report of an
analogous system operating in bacteria. This establishes
that bacteria could be used as a model system for further
studies probing the toxicity of anthracycline drugs.
This work establishes the proof-of-principle that environ-
mental bacteria can modify or degrade anticancer drugs,
and adds antineoplastic drug inactivation to the enzymatic
inactivation portfolio of actinomycetes. The tremendous
diversity of chemical modification ability represented in
our soil isolate library, which can be employed to modify or
degrade therapeutic drugs, can be screened for novel
activity on any number of therapeutic drugs. Selective
detoxification of drugs in noncancerous tissues could have
positive quality-of-life outcomes for chemotherapy patients.EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions
Strains used for cloning or conjugation were E. coli TOP10 (Invitrogen) and
E. coli ET12567/PU8002, respectively. E. coli were grown and maintained at264, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1261
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Bacterial Degradation of Doxorubicin37C in Luria-Bertani (LB) media or LB agar (LB with 1.5% agar) supplemented
with 100 ml/ml ampicillin, 50 mg/ml kanamycin, and/or 50 mg/ml apramycin,
when required.
Streptomyces strains were obtained from the spore stocks of the actino-
mycete library constructed by D’Costa et al. (2006). Additional Streptomyces
strains were obtained from the genome-sequenced collection at the Broad
Institute.
Streptomyces strains were grown and maintained at 30C in liquid Strepto-
myces isolation medium (D’Costa, et al., 2006) or Bennett’s medium (modified
from Jones, 1949; 1% potato starch, 0.2% cassamino acids, 0.18% yeast
extract, and 2 ml of Czapek mineral mix [per 100 ml: 10 g KCl, 10 g
MgSO4$7H2O, 12 g NaNO3, 0.2 g FeSO4$7H2O, and 200 ml concentrated
HCl]). Solid media used in culture plates were Bennett agar (Bennett with
1.5% agar) or Manitol-Soy agar (2% mannitol, 2% soya bean meal, 10 mM
MgCl2, 1.5% agar) supplemented with apramycin (50 mg/ml) and nalidixic
acid (30 mg/ml), when required.
Anthracyclines doxorubicin (Novopharm) and daunorubicin (Erfa Canada)
were purchased from McMaster Hospital pharmacy; additional doxorubicin
was obtained from AK Scientific. Antibiotics were obtained from Sigma or
BioShop.
Screen for Anthracycline Resistance among Soil Isolates
The spore stocks generated by D’Costa et al. (2006) were used as the inoc-
ulum for Streptomyces strains. These stocks were diluted 10X to create
a daughter library plate, from which 10 ml were applied to three 96-well plates
containing 200 ml solid Bennett’s agar supplemented or not with doxorubicin
(150 mg/ml). The screen was performed in duplicate, screening a total of 626
individual actinomycete strains. Plates were incubated for 3 days at 30C
before scoring by eye. Growth was ranked on a scale from 0 to 3 (no growth
to dense growth), and resistant strains were identified as those that ranked
two to three on both replicates.
To follow up on the mechanism of resistance in strains, 5 ml cultures in
Bennett’s medium were grown in the presence or absence of 150 mg/ml
doxorubicin. After growth at 30C with shaking at 250 rpm in the absence of
light, the cultures were lyophilized. Drug and metabolites were extracted by
the addition of 200–500 ml of methanol followed by centrifugation at
16,100 3 g for 10 min. Extracts were stored in the dark at 4C until samples
were analyzed.
Methanol extracts were analyzed by high-pressure liquid chromatography
(HPLC) and subsequent liquid chromatography with mass spectrometry
(LC/MS).
HPLC and LC/MS Analysis
Fractions were analyzed by HPLC and LC/MS using a guard plus Dionex
Acclaim 120 C18 column (3 mm 120 A˚ 4.6 3 150 mm). For HPLC, the sepa-
ration was performed using a flow rate of 1 ml/min under a gradient of aceto-
nitrile complemented with 0.05% trifluoroacetic acid (solvent B) in water
complemented with 0.05% trifluoroacetic acid (solvent A), and analyses
were made under UV light at various wavelengths (200 nm, 220 nm,
259 nm, 300 nm, and 340 nm). For LC/MS, the separation was performed
using a flow rate of 1 ml/min under a gradient of acetonitrile complemented
with 0.05% formic acid (solvent B) in water complemented with 0.05% formic
acid (solvent A), and analyses were made under UV light at wavelengths from
220 to 500 nm.
Anthracycline Degradation Tests
Doxorubicin degradation test reactions contained 150 mg/ml doxorubicin
and a cofactor recycling system consisting of 1 mM NADP+, 40 mM glucose
6-phosphate, and 0.3 units of glucose 6-phosphate dehydrogenase, in
addition to various quantities of protein fractions (usually 50–300 mg total
protein, as judged by Bradford assay). The reactions were incubated from 3
to 16 hr at 30C. After incubation, methanol was added to the reaction mix
(50:50 vol/vol), and the results were analyzed by TLC and LC/MS. TLC was
performed on silica plates (Algram SIL G/UV254 0.22 mm Silica gel 60) with
a mixture chloroform:methanol (9:1), as the mobile phase. The plates were
then visualized by eye and scanned under normal light conditions. The results
were confirmed by LC/MS (Qtrap, Applied Biosystems) in the same conditions
described before.1262 Chemistry & Biology 19, 1255–1264, October 26, 2012 ª2012 EEnzymatic Preparation of Doxorubicin Derivatives for NMR Analysis
To prepare for NMR, 6 mg of doxorubicin were mixed with 40 mM glucose-6-
phosphate, 1 mM NADP+, 120,000 units G6P dehydrogenase, and 5 mg of
purified NuoEFG complex. This mixture was incubated overnight at 30C
and lyophilized. The lyophilized pellet was resuspended in 100% DMSO and
passed through a reverse phase column (C18). The fractions were then
analyzed by NMR. 1D and 2D NMR experiments (correlated spectroscopy,
heteronuclear single quantum coherence spectroscopy, and heteronuclear
multiple-bond correlation spectroscopy) were carried out in DMSO-d6
(Cambridge Isotope Laboratories Inc.) using a Bruker AVIII 700 MHz
instrument. Chemical shifts are reported in ppm relative to tetramethylsilane
using the residual solvent signals at 2.50 and 39.50 ppm as internal references
for the 1H and 13C spectra, respectively.
Activity-Based Purification of the Putative Anthracycline
Degradation Enzyme
WAC04685 was grown in liquid Bennett media for 3 days at 30C with
shaking. After lysis by cell disruptor, ammonium sulfate precipitation was
used to concentrate the target proteins. The precipitate from 10% ammo-
nium sulfate was discarded, and the precipitate from the fraction between
10% and 60% ammonium sulfate was collected. Precipitated material was
resuspended in the minimal volume of 50 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) pH 7.5, 1 M ammonium sulfate possible. The
resuspended material was loaded onto a hand-poured XK-50 FPLC column
containing 60 ml of phenyl Sepharose 6 FF (GE Healthcare) resin, and the
proteins were eluted using a gradient of 50 mM HEPES pH 7.5. The active
fractions were pooled and loaded onto a hand-poured XK-16 column
containing 60 ml of Cibacron Blue Sepharose and the proteins were eluted
using a gradient of 50 mM HEPES pH 7.5, 1 M NaCl. The active protein
pool was then desalted and separated on an analytical Superdex 200 10/
300 GL gel filtration column (GE Healthcare). Pooled active protein was
loaded onto a 1 ml Q Sepharose HP column (GE Healthcare) and eluted
with 50 mM HEPES pH 7.5, 1 M NaCl. Finally, the active fractions
were pooled and separated by gravity chromatography through 1 ml hydrox-
yaptatite gel (BioGel HTP gel, Biorad), and elution was with 50 or 100 mM
sodium phosphate buffer pH 7. All active fractions were analyzed by SDS-
PAGE and native PAGE gel, and the gels were stained by Coomassie blue
or silver.
Peptide Mass Fingerprinting of the Putative Anthracycline
Degradation Enzyme
The protein gel spots/bands were destained with 50 mM ammonium bicar-
bonate and water until clear, then rinsed with water. The spots were then
reduced with 10 mMDTT at 55C for 30 min and alkylated with 100 mM iodoa-
cetamide at room temperature for 15 min in the dark. Proteins were digested
in situ with 30 ml (13 ng/ml) trypsin (Promega Corporation, Madison WI) in
50 mM ammonium bicarbonate at 37C overnight, followed by peptide
extraction with 30 ml of 5% formic acid, and then 30 ml of acetonitrile.
Nanoscale Microcapillary Liquid Chromatography Electrospray
Ionization Tandem Mass Spectrometry
The pooled extracts were concentrated to less than 5 ml on a SpeedVac spin-
ning concentrator and then brought up in 0.1% formic acid/5% acetonitrile
for protein identification by microflow liquid chromatography electrospray
tandem mass spectrometry (microLC-ESI-MS/MS) using a ThermoFisher
LTQ-XL-Orbitrap Hybrid Mass Spectrometer (ThermoFisher, Bremen,
Germany) coupled to an Eksigent nanoLC-2D HPLC system (Eksigent,
Dublin, CA). Chromatography was performed using 0.1% formic acid in
both the A solvent (98% water, 2% acetonitrile) and B solvent (80% aceto-
nitrile, 10% isopropanol, 10% water) and a 5% B to 95% B gradient over
30 min at 5 ml/min through an Eksigent capillary (CSP-3 C18-100, 0.3 m 3
100 mm) column. The LTQ-XL-Orbitrap mass spectrometer experiment
was set to perform a Fourier transform (FT) full scan from 200-2000 m/z
with resolution set at 60,000 (at 500 m/z), followed by linear ion trap MS/
MS scans on the top five ions. Dynamic exclusion was set to 2 and selected
ions were placed on an exclusion list for 30 s. The lock-mass option was
enabled for the FT full scans using the ambient air polydimethylcyclosiloxane
ion of m/z = 445.120024 or a common phthalate ion m/z = 391.284286 for
real time internal calibration.lsevier Ltd All rights reserved
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Tandem mass spectra were extracted and converted in extensible markup
language and Mascot-generating files. All MS/MS samples were analyzed
using X! Tandem and Mascot database. X! Tandem and Mascot were set up
to search the National Center for Biotechnology Information and Swissprot
database (699,052 entries), assuming the digestion enzyme Trypsin. X!
Tandem and Mascot were searched with a fragment ion mass tolerance of
0.40 Da and a parent ion tolerance of 10.0 ppm. The oxidation of methionine
and the iodoacetamide derivative of cysteine were specified in X! Tandem
and Mascot as variable modifications. Protein identifications were accepted
if they could be established at greater than 95.0% probability and contained
at least three identified peptides.
Kinetics of Doxorubicin Degradation
To determine the kinetic constants of the degradation complex, we followed
the oxidation of NADH at 340 nm. To do so, 12.5 mmol of NADH were mixed
with 0.47 mg of protein complex in the presence of various amounts of doxo-
rubicin (from 0 to 700 mM), and the reaction was monitored using a microplate
reader (Spectramax 384 plus, Molecular Devices) for a period of 360 s. The
rates were then plotted using Graphit 1.0 software.
Genome Sequencing of Strain WAC04685 and Manipulation of Its
NuoF Homolog
Genomic DNA was prepared using a DNEasy Blood and Tissue Kit (QIAGEN),
following the Gram-positive bacteria protocol. Sequencing on the Illumina
platform was performed at Ambry Genetics (Aliso Viejo, CA). From this,
3,560,391 paired-end reads (7,120,872 reads total) as 72-mers were used
for assembly for a total of 512,702,784 bp. The average length of fragments
was 325 bp, for an average insert length of 181 bp. Assembly of Illumina reads
was accomplished using Velvet (version 0.7.63; http://www.ebi.ac.uk/
zerbino/velvet/). Values for the length parameter (k) and the coverage cutoff
(kmer) were 31 and 8, respectively. After assembly, the genome was revealed
to be about 7.8Mbp andwas in 1,916 contigs (about 1,700 bp/contig). The N50
was 8,566, and the GC% was 71.37%.
nuoF Disruption in WAC04685
A suicide plasmid was generated to disrupt nuoF by single recombination in
WAC04685. Therefore, a 978 bp internal portion of nuoF was amplified by
PCR with the WAC04685 genomic DNA as template, using the primers 50ATA
CTG ATC AAG CTT GGA CTC CGG TCT GCG CGG 30 and 50ATA ATA GAA
TTC TTG TCG AGG TCG GAC ATC ACG 30, containing, respectively, the Hind
III (Fermentas) and EcoRI (Fermentas) restriction sites. The amplicon was di-
gested and ligated to thepSET152 vector digestedby the sameenzymes, gene-
rating the pEM1 plasmid. The plasmidwas then used to transform E. coli ET/PU
by electroporation (Dunican and Shivnan, 1989). Mobilization of plasmids from
E. coli to Streptomyces WAC04685 strains was done essentially as described
by Scha¨fer et al. (1990). Transconjugants were selected on MS agar and
overlaid with apramycin (50 mg/ml) and nalidixic acid (30mg/ml). The presence
of integration was analyzed further by growing the transconjugant colonies
on Bennett agar in the presence of apramycin (50 mg/ml), and the disruption
of nuoFwas confirmed by PCR performed on the genomic DNA of themutants.
Activity Tests for the Disruption Mutants
The WAC04685 mutants containing pEM1 were grown in 200 ml of Bennett
liquid media supplemented with apramycin (50 mg/ml) during 3 days at
30C. The cells were then collected, resuspended in HEPES 50 mM, pH 7.5,
and disrupted with a cell disruptor. The lysate was centrifuged, and an anthra-
cycline degradation test was made on the supernatant, as described above.
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